Pre-Made Anselamimab biosimilar, Whole mAb, Anti-SAA1 Antibody: Anti-PIG4/SAA/SAA2/TP53I4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pre-made Anselamimab benchmark antibody ( Whole mAb, anti-SAA1 therapeutic antibody, Anti-PIG4/SAA/SAA2/TP53I4 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-654
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Products Name (INN Index) | Pre-Made Anselamimab biosimilar, Whole mAb, Anti-SAA1 Antibody: Anti-PIG4/SAA/SAA2/TP53I4 therapeutic antibody |
---|---|
INN Name | Anselamimab |
Target | SAA1 |
Format | Whole mAb |
Derivation | Humanized |
Species Reactivity | Chimeric |
CH1 Isotype | G1 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Phase-II |
Est. Status | Active |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2021 |
Year Recommended | NA |
Companies | Caelum Biosciences |
Conditions Approved | NA |
Conditions Active | AA amyloidosis |
Conditions Discontinued | NA |
Development Tech | NA |
Previous Name | NA |
Gm Offical Target Name | SAA1 |
Package |
Genemeidi Omicron Variant Products
test
Previous slide
Next slide